Veru (VERU) to Announce Quarterly Earnings on Tuesday

Veru (NASDAQ:VERU) will likely be announcing its Q3 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.34) per share and revenue of $1.70 million for the quarter. Individuals may visit the the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.15. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru Trading Up 4.2%

Shares of VERU traded up $0.10 during trading hours on Tuesday, reaching $2.35. 129,790 shares of the company’s stock traded hands, compared to its average volume of 882,393. The stock has a market cap of $37.80 million, a PE ratio of -2.65 and a beta of -1.19. The firm’s 50 day simple moving average is $2.71 and its 200-day simple moving average is $2.51. Veru has a 12 month low of $2.05 and a 12 month high of $7.33.

Institutional Trading of Veru

Several hedge funds have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new position in shares of Veru during the fourth quarter valued at about $2,140,000. Marshall Wace LLP bought a new stake in shares of Veru in the 2nd quarter valued at about $220,000. Osaic Holdings Inc. boosted its holdings in Veru by 11.9% during the 2nd quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock valued at $152,000 after acquiring an additional 27,954 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Veru during the 2nd quarter valued at about $152,000. Finally, Sender Co & Partners Inc. grew its position in Veru by 82.8% during the 2nd quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock worth $139,000 after acquiring an additional 107,911 shares during the last quarter. 47.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on VERU. Weiss Ratings cut shares of Veru from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Veru in a report on Thursday, June 4th. Oppenheimer cut their target price on shares of Veru from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Finally, Wall Street Zen raised Veru to a “hold” rating in a research note on Sunday, July 12th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.